Y Intercept Hong Kong Ltd Has $5.58 Million Stock Position in HCA Healthcare, Inc. (NYSE:HCA)

Y Intercept Hong Kong Ltd boosted its stake in shares of HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 209.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 18,587 shares of the company's stock after buying an additional 12,571 shares during the period. Y Intercept Hong Kong Ltd's holdings in HCA Healthcare were worth $5,579,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. FMR LLC lifted its position in HCA Healthcare by 322.3% in the 3rd quarter. FMR LLC now owns 3,141,769 shares of the company's stock worth $1,276,909,000 after buying an additional 2,397,883 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of HCA Healthcare by 120.1% during the 4th quarter. Principal Financial Group Inc. now owns 873,775 shares of the company's stock worth $262,264,000 after purchasing an additional 476,756 shares in the last quarter. Meritage Group LP bought a new position in HCA Healthcare during the third quarter valued at approximately $150,548,000. Canoe Financial LP increased its stake in shares of HCA Healthcare by 226,952.9% during the 4th quarter. Canoe Financial LP now owns 231,594 shares of the company's stock worth $69,513,000 after purchasing an additional 231,492 shares during the last quarter. Finally, Holocene Advisors LP boosted its holdings in HCA Healthcare by 210.6% in the third quarter. Holocene Advisors LP now owns 306,796 shares of the company's stock worth $124,691,000 after purchasing an additional 208,015 shares in the last quarter. 62.73% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, SVP Jennifer Berres sold 9,533 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $322.59, for a total transaction of $3,075,250.47. Following the completion of the transaction, the senior vice president now directly owns 15,412 shares of the company's stock, valued at approximately $4,971,757.08. This represents a 38.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.60% of the company's stock.

HCA Healthcare Trading Up 0.2 %

Shares of HCA traded up $0.64 during trading hours on Thursday, reaching $320.55. The stock had a trading volume of 1,788,584 shares, compared to its average volume of 1,694,602. The firm has a 50-day moving average of $314.65 and a 200 day moving average of $350.12. The company has a quick ratio of 0.97, a current ratio of 1.08 and a debt-to-equity ratio of 69.07. The company has a market cap of $79.60 billion, a P/E ratio of 14.59, a P/E/G ratio of 1.10 and a beta of 1.64. HCA Healthcare, Inc. has a 52 week low of $289.98 and a 52 week high of $417.14.

HCA Healthcare (NYSE:HCA - Get Free Report) last issued its quarterly earnings data on Friday, January 24th. The company reported $6.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.03 by $0.19. HCA Healthcare had a return on equity of 586.47% and a net margin of 8.16%. During the same period last year, the firm posted $5.90 earnings per share. On average, sell-side analysts expect that HCA Healthcare, Inc. will post 24.98 earnings per share for the current fiscal year.

HCA Healthcare Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 17th will be issued a dividend of $0.72 per share. This is a boost from HCA Healthcare's previous quarterly dividend of $0.66. The ex-dividend date is Monday, March 17th. This represents a $2.88 annualized dividend and a yield of 0.90%. HCA Healthcare's dividend payout ratio is presently 13.11%.

Analyst Upgrades and Downgrades

HCA has been the subject of several analyst reports. Barclays reduced their target price on HCA Healthcare from $392.00 to $366.00 and set an "overweight" rating for the company in a report on Monday, January 27th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $405.00 price target on shares of HCA Healthcare in a research report on Monday, January 27th. Morgan Stanley dropped their price target on HCA Healthcare from $406.00 to $355.00 and set an "equal weight" rating on the stock in a research report on Tuesday, December 17th. Bank of America cut their price target on HCA Healthcare from $380.00 to $370.00 and set a "buy" rating for the company in a report on Monday, January 27th. Finally, KeyCorp reduced their target price on HCA Healthcare from $420.00 to $370.00 and set an "overweight" rating for the company in a research report on Tuesday, January 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $385.67.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.